Cover Image
市場調查報告書

Catabasis Pharmaceuticals, Incx:產品平台分析

Catabasis Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256100
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
Catabasis Pharmaceuticals, Incx:產品平台分析 Catabasis Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年06月17日 內容資訊: 英文 36 Pages
簡介

Catabasis Pharmaceuticals, Inc. 是發現、開發發炎性疾病和代謝障礙的治療藥的生物科技企業。 該公司結合獨有的代謝及標的技術進行產品開發、製圖。

本報告提供Catabasis Pharmaceuticals, Inc.的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

Catabasis Pharmaceuticals, Inc.的基本資料

  • Catabasis Pharmaceuticals, Inc.概要
  • 主要資訊
  • 企業資料

Catabasis Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Catabasis Pharmaceuticals, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Catabasis Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式

Catabasis Pharmaceuticals, Inc.:藥物簡介

  • CAT-2003
  • CAT-1000 Series
  • CAT-1004
  • CAT-1040
  • CAT-1041
  • CAT-1920
  • CAT-2000 Series
  • CAT-2054
  • CAT-4000 Series
  • CAT-4001

Catabasis Pharmaceuticals, Inc.:開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Catabasis Pharmaceuticals, Inc.:最近的開發平台趨勢

Catabasis Pharmaceuticals, Inc.:暫停中的計劃

Catabasis Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07179CDB

Summary

Global Markets Direct's, 'Catabasis Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Catabasis Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Catabasis Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Catabasis Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Catabasis Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Catabasis Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Catabasis Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Catabasis Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Catabasis Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Catabasis Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Catabasis Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Catabasis Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Catabasis Pharmaceuticals, Inc. Snapshot
    • Catabasis Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Catabasis Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Catabasis Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Catabasis Pharmaceuticals, Inc. - Pipeline Products Glance
    • Catabasis Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Catabasis Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Catabasis Pharmaceuticals, Inc. - Drug Profiles
    • CAT-2003
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAT-1004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAT-1000 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAT-2054
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAT-1040
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAT-1041
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAT-1920
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAT-2000 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAT-4000 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAT-4001
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Catabasis Pharmaceuticals, Inc. - Pipeline Analysis
    • Catabasis Pharmaceuticals, Inc. - Pipeline Products by Target
    • Catabasis Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Catabasis Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Catabasis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Catabasis Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Catabasis Pharmaceuticals, Inc. - Dormant Projects
  • Catabasis Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Catabasis Pharmaceuticals, Inc., Key Information
  • Catabasis Pharmaceuticals, Inc., Key Facts
  • Catabasis Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Catabasis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Catabasis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Catabasis Pharmaceuticals, Inc. - Phase II, 2015
  • Catabasis Pharmaceuticals, Inc. - Phase I, 2015
  • Catabasis Pharmaceuticals, Inc. - Preclinical, 2015
  • Catabasis Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Catabasis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Catabasis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Catabasis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Catabasis Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Catabasis Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Catabasis Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Catabasis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Catabasis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Catabasis Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Catabasis Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Catabasis Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Catabasis Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top